Top Story

Vosaroxin combination demonstrated improved survival in AML

December 20, 2014

SAN FRANCISCO — Farhad Ravandi, MD, professor of medicine in the department of leukemia at The University of Texas MD Anderson Cancer Center, discusses data from the VALOR trial.

In the phase 3 study, combination therapy with vosaroxin (Quinprezo, Sunesis) and cytarabine was associated with longer OS in a cohort of more than 700 patients with acute myeloid leukemia.

New next-generation sequencing test launched for thyroid nodules

December 20, 2014
Interpace Diagnostics, a molecular diagnostics subsidiary of PDI, Inc., has recently launched a new next-generation sequencing test designed to determine the difference…
In the Journals

ST2 levels predicted acute GVHD, mortality after double-unit cord blood transplantation

December 19, 2014
High levels of the biomarker suppressor of tumorigenicity 2 at 28 days post-cord blood transplantation independently predicted acute graft-versus-host disease, according…
In the Journals

Anticoagulant, antiplatelet medications carry rare dermatologic surgery hemorrhage risks

December 19, 2014
Dermatologists and dermatologic surgeons should be aware of the bleeding risks of anticoagulant and antiplatelet drugs used for cardiovascular diseases, according to…
In the Journals

Nonenhanced neck CT may detect diffuse thyroid disease

December 19, 2014
Nonenhanced CT images are effective for differentiating diffuse thyroid disease from normal thyroid, according to recent findings published in the International Journal
More News Headlines »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
thumbnail for video 3949008667001

Data show encouraging advances in treatment of AML

December 17, 2014
SAN FRANCISCO – According to preliminary data presented at the ASH Annual Meeting and Exposition, FLT3 inhibitors…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
morganatic-roan